

Table 1- Demographics, clinical presentation, imaging, and CSF autoantibody results in adults versus children

	Pediatric (n=67)	Adult (n=35)	P- value
Mean age in years (SD)	10.1 (\pm 4.7)	54.6 (\pm 21.5)	<0.001
Median age in years (range)	11 (1-18)	63 (20-88)	
Gender, Female, n (%)	39 (58.2%)	19 (54.3%)	0.432
Race, White, n (%)	29 (43.3%)	29 (83%)	<0.001
Cognition/Memory changes, n (%)	54 (80.6%)	24 (68.6%)	0.220
Altered Sensorium, n (%)	36 (53.7%)	27 (77.1%)	0.031
Psychiatric symptoms, n (%)	44 (65.7%)	7 (20%)	<0.001
Sleep abnormalities, n (%)	38 (56.7%)	5 (14.3%)	<0.001
Seizures, n (%)	31 (46.3%)	15 (42.9%)	0.453
Focal seizures, n (%)	32 (47.8%)	5 (14.3%)	0.004
Status epilepticus, n (%)	13 (19.4%)	2 (5.7%)	0.054
Abnormal EEG, n(%)	57 (85%)	27 (77%)	0.363
Diffuse Slowing, n(%)	29 (43%)	18 (51.4%)	-
Focal Slowing, n(%)	8 (12%)	5 (16%)	-
Focal Spikes, n(%)	19 (28%)	4 (11%)	-
Delta Brush, n(%)	1 (1.5%)	-	-
Normal, n(%)	7 (10.4%)	5 (14%)	-
Abnormal MRI, n(%)	16 (24%)	18 (51%)	0.001
Medial temporal/Hippocampi, n(%)	5 (7.5%)	3 (8.6%)	-
Multifocal, n(%)	5 (7.5%)	5 (14.3%)	-
Parieto-Occipital , n(%)	-	3 (8.6%)	-
Basal Ganglia, n(%)	3 (4.5%)	-	-
Brain Stem, n(%)	1 (1.5%)	4 (11.4%)	-
Miscellaneous, n(%)	2 (3%)	3 (8.6%)	
CSF Antibody Seropositivity, n(%)	35 (52.2%)	20 (57.1%)	0.347
CSF Anti- NMDA seropositivity, n(%)	28 (41.8%)	8 (22.9%)	0.044
Steroids	59 (88%)	35 (100%)	0.562
IVIG	57 (85%)	19 (54.3%)	0.001
Plasma Exchange	34 (51%)	14 (40%)	0.205
Rituximab	18 (27%)	4 (11%)	0.058